Say TJ, don't underestimate the value of the phase to head and neck cancer trial. It's a single arm, and they're going it alone just to test specifically if immunopulse can increase the T I L environment. They mentioned in the conference call the importance of Immunopulse as a monotherapy for H&N. There is an abundance of head and neck cancer patients, the dosing schedule will be the same as melanoma, you don't need a lot of sites and they could complete an interim result maybe even sooner than the combination trial with melanoma.
From my understanding, if they did just the combination trial, The data could be confounding – – meaning it could be said that the higher TIL environment is being generated not by immunopulse alone, but only as it works with Keytruda. So from my perspective, the phase 2 is positioned powerfully to confirm any positive increase in till environment from the melanoma data.
News 
Market Data 
Discover 
